RPRX Stock: Price, Earnings History and SEC Filings
Royalty Pharma plc (RPRX) last traded at $67.18, up 1.90% on the latest session and up 15.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.32 against an analyst estimate of $1.27, a beat of 3.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RPRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $1.32 | $1.27 | +3.94% |
| Mar 2026 | May 6, 2026 | $1.30 | $1.22 | +6.56% |
| Dec 2025 | Feb 11, 2026 | $1.46 | $1.33 | +9.77% |
| Sep 2025 | Nov 5, 2025 | $1.17 | $1.11 | +5.41% |
RPRX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How RPRX reacts to earnings
Across its last 8 earnings releases, RPRX moved 3.2% on average the next session, in either direction. It rose after 7 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | +0.47% |
| 2026-05-06 | Before open | +0.56% |
| 2026-02-11 | Before open | +0.09% |
| 2025-11-05 | Before open | +6.82% |
| 2025-08-06 | Before open | -2.08% |
| 2025-05-08 | Before open | +1.07% |
| 2025-02-11 | Before open | +1.67% |
| 2025-01-10 | Before open | +12.56% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RPRX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2.4B | $771M | – | 32.4% | $1.78 |
| 2024 | $2.3B | $859M | – | 37.9% | $1.91 |
| 2023 | $2.4B | $1.1B | – | 48.2% | $2.53 |
| 2022 | $2.2B | $43M | – | 1.9% | $0.10 |
| 2021 | $2.3B | $620M | – | 27.1% | $1.49 |
| 2020 | $2.1B | $975M | – | 45.9% | $1.32 |
| 2019 | $1.8B | $2.3B | – | 129.4% | – |
| 2018 | $1.8B | $1.4B | – | 76.8% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RPRX
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 4, 2026Shareholder vote
- 8-K · May 28, 2026Material agreement, New financial obligation, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Apr 13, 2026Regulation FD disclosure
- DEF 14A · Apr 10, 2026
- 10-K · Feb 11, 2026
- 8-K · Feb 11, 2026Results of operations, Financial statements and exhibits
Insider filing activity
RPRX insiders filed 10 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RPRX news
- Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision NearsOct 30, 2026 · marketbeat.com
- Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key MetricsOct 30, 2026 · finance.yahoo.com
- Should You Buy Royalty Pharma Stock Before Nov. 4?Oct 29, 2026 · fool.com
- Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOct 28, 2026 · finance.yahoo.com
- Funds Load Up On Marriott, Estee Lauder As Big Tech Earnings LoomOct 28, 2026 · finance.yahoo.com
- Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters InsteadOct 25, 2026 · fool.com
- Missed Royalty Pharma's Rally? Here's The Case Holders BackedOct 24, 2026 · finance.yahoo.com
About Royalty Pharma plc
Royalty Pharma plc (RPRX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in United Kingdom. Its fiscal year ends in December.